Summary of AEs
| . | Nilotinib (n = 101) . | Imatinib (n = 103) . | ||
|---|---|---|---|---|
| . | All grades, n (%) . | Grade 3/4, n (%) . | All grades n (%) . | Grade 3/4, n (%) . |
| AEs | 100 (99.0) | 49 (48.5) | 93 (90.3) | 23 (22.3) |
| Serious AEs | 18 (17.8) | 14 (13.9) | 13 (12.6) | 11 (10.7) |
| AEs leading to discontinuation | 20 (19.8) | 10 (9.9) | 6 (5.8) | 4 (3.9) |
| AEs requiring dose interruption and/or change | 59 (58.4) | 32 (31.7) | 17 (16.5) | 6 (5.8) |
| . | Nilotinib (n = 101) . | Imatinib (n = 103) . | ||
|---|---|---|---|---|
| . | All grades, n (%) . | Grade 3/4, n (%) . | All grades n (%) . | Grade 3/4, n (%) . |
| AEs | 100 (99.0) | 49 (48.5) | 93 (90.3) | 23 (22.3) |
| Serious AEs | 18 (17.8) | 14 (13.9) | 13 (12.6) | 11 (10.7) |
| AEs leading to discontinuation | 20 (19.8) | 10 (9.9) | 6 (5.8) | 4 (3.9) |
| AEs requiring dose interruption and/or change | 59 (58.4) | 32 (31.7) | 17 (16.5) | 6 (5.8) |